A Phase I Study of Single and Multiple Doses of VG290131 in Healthy Subjects

This is a randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability and PK profiles of orally administered VG290131 in healthy subjects. The main questions it aims to answer are: 1. The safety and tolerability of VG290131 when administered orally as a single dose and multiple doses in healthy subjects. 2. The pharmacokinetic (PK) profiles of VG290131 and the food effect on the PK profiles of VG290131 in healthy subjects. Approximately 86 subjects will be enrolled in the study.

NCT Number	NCT06081465
Lead Sponsor	Zhejiang Vimgreen Pharmaceuticals, Ltd. Collaborators: Tigermed Consulting Co., Ltd
Conditions	Healthy Volunteers
Enrollment	86 participants
Start Date	2023-10-20
Primary Completion	2024-12 (estimated)
Study Completion	2024-12 (estimated)
Updated on ClinicalTrials.gov	2024-07-26